REKINDLE THERAPEUTICS
REKINDLE THERAPEUTICS
Industry:
Biotechnology Life Science Pharmaceutical
Founded:
2018-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Total Employee:
1+
Status:
Active
Contact:
(617) 669-0509
Total Funding:
1.1 M USD
Similar Organizations
AcureX Therapeutics
AcureX Therapeutics is a biotechnology company.
Capienda Biotech
Drug Discovery and Biotechnology
Courier Therapeutics
Courier Therapeutics is a biotechnology.
Emendo Biotherapeutics
Emendo Biotherapeutics is a biotechnology company
GeneWorx Capital
GeneWorx Capital is a technology venture development firm.
Lumosa Therapeutics
Lumosa Therapeutics, a public traded company i
Neuroene Therapeutics
Neuroene Therapeutics is a startup biotechnology company.
Pointcare Genomics
Pointcare Genomics Corporation is a biotech company.
Primmune Therapeutics
Primmune Therapeutics is a Biotechnology company.
RNADerm Therapeutics
RNADerm Therapeutics is a biotechnology company.
Savefruit
Savefruit is a biotechnology company.
Telum Therapeutics
Telum Therapeutics is a biotechnology company.
Tennessee Extracts
Tennessee Extracts is a biotechnology company.
TheraPten Biosciences
TheraPten Biosciences is a Canadian preclinical biotechnology company.
Venn Therapeutics
Venn Therapeutics is a privately held immuno-oncology company.
VivaZome Therapeutics
VivaZome Therapeutics is Australian biotech company,
XRad Therapeutics
XRad Therapeutics is a Biotechnology company.
Current Employees Featured
More informations about "Rekindle Therapeutics"
Rekindle Therapeutics - Crunchbase Company Profile & Funding
Rekindle Therapeutics is a biotechnology company. Where is Rekindle Therapeutics's headquarters? Rekindle Therapeutics is located in Cambridge, Massachusetts, United States. …See details»
Rekindle Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Rekindle Therapeutics is a biotechnology company.See details»
Rekindle Therapeutics - Contacts, Employees, Board Members
Rekindle Therapeutics has 1 current employee profile, CEO Detlev Biniszkiewicz. Rekindle Therapeutics is a biotechnology company.See details»
Detlev Biniszkiewicz - Managing Director at MPM …
Dr. Detlev Biniszkiewicz is President and CEO of two early-stage MPM portfolio companies, Rekindle Therapeutics and NextPoint Therapeutics. Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep …See details»
Rekindle Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Rekindle Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, .See details»
Rekindle Therapeutics - Products, Competitors, Financials, …
Rekindle Therapeutics's headquarters is located at 450 Kendall Street, Cambridge. What is Rekindle Therapeutics's latest funding round? Rekindle Therapeutics's latest funding round is …See details»
ReCode Therapeutics - Powering the future of genetic …
ReCode is the first genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver. Our pipeline of rare disease therapeutics uses optimized mRNA and gene correction with redosing capability.See details»
Mitochondrial PD-L1 modulates cancer immunotherapy | Cell …
Jan 24, 2023 · In a recent paper published in Cell Research, Xie et al. report that promoting mitochondrial distribution of PD-L1 through targeting the ATAD3A-PINK1-mitophagy axis is a …See details»
Rekindle Therapeutics Stock Price, Funding, Valuation, Revenue ...
Nov 2, 2018 · See Rekindle Therapeutics funding rounds, investors, investments, exits and more. Evaluate their financials based on Rekindle Therapeutics's post-money valuation and revenue.See details»
Post-translational regulations of PD-L1/PD-1: Mechanisms and ...
Here, we provide an update of current progress of PD-L1 and PD-1 post-translational regulations and highlight the mechanism-based combination therapy strategies for a better treatment of …See details»
Frontiers | Light-Controllable PROTACs for Temporospatial Control …
PROteolysis-TArgeting Chimeras (PROTACs) is an emerging and promising approach to target intracellular proteins for ubiquitination-mediated degradation, including those so-called …See details»
Amino acid availability governs mTOR ubiquitination
Dec 15, 2023 · In a recent paper published in Cell Metabolism, Ge et al. report that amino acid depletion promotes K27-linked poly-ubiquitination of mTOR through activating a novel tRNA …See details»
Extracellular and nuclear PD-L1 in modulating cancer …
Sep 1, 2021 · Combining PD-1/PD-L1 blockade with inhibition of exosomal PD-L1 secretion significantly reduces tumor growth and increases overall survival in syngeneic mouse models.See details»
Rekindle Therapeutics - Crunchbase
Rekindle Therapeutics is a biotechnology company.See details»
O-GlcNAcylation in tumorigenesis and its implications for cancer ...
Jun 20, 2024 · O-GlcNAcylation occurs on key proteins involved in chromatin organization, transcription mechanisms, and epigenetic regulation, thus reprogramming an oncogenic …See details»
Mitochondrial PD-L1 modulates cancer immunotherapy - Nature
In a recent paper published in , Xie et al. report that promoting Cell Research mitochondrial distribution of PD-L1 through targeting the ATAD3A-PINK1-mitophagy axis is a promising …See details»
Light-Controllable PROTACs for Temporospatial Control of Protein ...
Jul 19, 2021 · In this review, we summarize the emerging light-controllable PROTACs and the prospective for other potential ways to achieve temporospatial control of PROTACs. …See details»
Post-translational regulations of PD-L1 and PD-1: Mechanisms and ...
Oct 1, 2022 · Antibodies targeting programmed cell death protein 1 (PD-1) or its ligand programmed death-ligand 1 (PD-L1) are profoundly changing the methods to treat cancers …See details»
Metabolic orchestration of cell death by AMPK-mediated ... - Science
Jun 29, 2023 · Our studies reveal that AMPK phosphorylation of RIPK1 represents a crucial metabolic checkpoint, which dictates cell fate response to metabolic stress, and highlight a …See details»
Cancer Therapeutics Innovation Pipeline (CTIP)
Figure 1: The Cancer Therapeutics Innovation Pipeline: Stages, deliverables, major activities, and funding sources.. CTIP funds projects in four stages of preclinical drug discovery as shown in …See details»